



Pharmaceuticals with Estimated Retail Cost Greater than \$1 Million Annually per Covered Life (as of 5.20.20)

Pharmaceutical	Condition
Acthar® (repository corticotropin injection)	Stevens-Johnson Syndrome
Acthar® (repository corticotropin injection)	Sarcoidosis
Acthar® (repository corticotropin injection)	Serum Sickness
Acthar® (repository corticotropin injection)	Nephrotic Syndrome
Aldurazyme® (laronidase)	Mucopolysaccharidosis (MPS)
Berinert® (C1 esterase inhibitor concentrate)	Hereditary Angioedema (HAE)
Cerezyme® (imiglucerase)	Gaucher Disease
Chenodal® (chenodiol)	Cholelithiasis (gallstones)
Cinryze® (C1 esterase inhibitor)	Hereditary Angioedema (HAE)
Elaprase® (idursulfase)	Mucopolysaccharidosis (MPS)
Exondys 51® (eteplirsen)	Duchenne Muscular Dystrophy (DMD)
Feiba NF® (anti-inhibitor coagulant complex)	Hemophilia A & B Prophylaxis
Firazyr® (icatibant)	Hereditary Angioedema (HAE)
Gamifant® (emapalumab-izsg)	Hemophagocytic Lymphohistiocytosis (HLH)
Haegarda® (C1 esterase inhibitor subcutaneous)	Hereditary Angioedema (HAE)
Kalbitor® (ecallantide)	Hereditary Angioedema (HAE)
Kymriah® (tisagenlecleucel)	Acute Lymphoblastic Leukemia (ALL)
Lumizyme® (alglucosidase alfa)	Pompe Disease
Mepsevii® (vestronidase alfa-vjvk)	Mucopolysaccharidosis (MPS)
Myalept® (metreleptin)	Leptin Deficiency
Naglazyme® (galsulfase)	Mucopolysaccharidosis (MPS)
Poteligeo® (mogamulizumab-kpkc)	Mycosis Fungoides/Cutaneous T-cell Lymphoma
Ravicti® (glycerol phenylbutrate)	Urea Cycle Disorders
Revcovi® (elapegedemase-lvlr)	Severe Combined Immune Deficiency (SCID)
Ruconest® (C1 esterase inhibitor recombinant)	Hereditary Angioedema (HAE)
Soliris® (eculizumab)	Atypical Hemolytic Uremic Syndrome (aHUS)
Soliris® (eculizumab)	Myasthenia Gravis
Soliris® (eculizumab)	Neuromyelitis Optica (NMO)
Soliris® (eculizumab)	Paroxysmal Nocturnal Hemoglobinuria (PNH)
Spinraza® (nusinersen)	Spinal Muscular Atrophy (SMA)
Strensiq® (asfotase alfa)	Hypophosphatasia / Hypophosphatemia
Takhzyro® (lanadelumab-flyo)	Hereditary Angioedema (HAE)
Targretin® (bexarotene)	Mycosis Fungoides/Cutaneous T-cell Lymphoma
Ultomiris® (ravulizumab-cwvz)	Paroxysmal Nocturnal Hemoglobinuria (PNH)
Vimizim® (elosulfase alfa)	Mucopolysaccharidosis (MPS)
Yescarta® (axicabtagene ciloleucel)	Non-Hodgkin Lymphoma (NHL)
Zolgensma® (onasemnogene abeparvovec-xioi)	Spinal Muscular Atrophy (SMA)

The trademarks above are the property of the respective trademark owner.

The amounts shown are estimates of the therapy retail list price but are not intended to be an indication of reasonable or customary cost. The trademarks above are the property of the respective trademark owner. Disclaimer: This document is confidential, contains proprietary information and is the intellectual property of PartnerRe America Insurance Company (PRAIC). Neither this document nor any of the information contained herein may be reproduced or disclosed under any circumstances without the express written permission of PRAIC. Please be aware that any independent use of this document and the information contained therein is strictly prohibited.